Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

vestigator for the Phase 1 and Phase 1b/2 clinical trials of voreloxin in AML. "Voreloxin appears to be a promising new drug for the treatment of AML and I look forward to the results of continued clinical investigation."

Copies of these poster presentations are available at http://www.sunesis.com.

About Voreloxin

Voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. In an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer, voreloxin has shown objective responses and been generally well-tolerated.

Conference Call Information

Sunesis management will host a conference call on Tuesday, December 9, 2008, at 11:00 a.m. ET / 8:00 a.m. PT to discuss the voreloxin and SNS-032 clinical data presented at ASH. Individual and institutional investors can access the call via 1-877-856-1956 (U.S. and Canada) or +1-719-325-4805 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on the company's website until December 23, 2008.

About Acute Myeloid Leukemia

AML is a rapid
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 /PRNewswire-iReach/ -- Today E-T-A Circuit ... Appliance Inlet Module. The X3130, integrated with E-T-A,s ... a C14 appliance inlet module, rocker switch and ... three-in-one device allows design engineers to streamline the ... installation time by 66 percent - and reduce ...
(Date:6/18/2013)... HILL, N.C. , June 18, 2013  Recent ... more difficult for Medical Education groups at large pharmaceutical ... on the safe and effective use of their new ... the pharma industry, it is crucial that these ... reaching healthcare professionals. To address the changes ...
(Date:6/18/2013)... , June 18, 2013  Specialty Coating ... breakthrough in Parylene coating technologies: SCS microRESIST™ ... benefits of Parylene with antimicrobial properties to ... and components. (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ... (HAIs) increase and continue to pose a ...
Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced ... esterase inhibitor [human]) therapy at the 6th Annual C1 ... Food and Drug Administration in October 2008 for routine ... adolescents. In February 2009, ViroPharma was granted priority review ...
... 26 Ascenta Therapeutics announced today that eleven presentations ... an oral, pan-Bcl-2 inhibitor, in several major tumor types ... Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in ... www.asco.org .(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ...
Cached Medicine Technology:Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 2Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 3Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 4Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 5Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 6Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop 7Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
(Date:6/19/2013)... Ore. A new understanding of the genetic process ... diagnosis of potentially dangerous lesions for some women, and ... anti-viral therapies in certain cases suggesting they could ... , The analysis provides a clearer picture of the ... human papillomavirus sometimes leads to chronic infection and, in ...
(Date:6/19/2013)... University of Iowa study reveals significant disparities between ... completing substance abuse treatment programs. Moreover, these disparities ... "Our findings suggest that for most states there,s ... of psychiatry and biostatistics. "There are strong racial ... to complete substance abuse treatment programs successfully, and ...
(Date:6/19/2013)... In early April, senior leaders from medical, law ... to discuss one question: how can first responders improve ... The preliminary results of this discussion are now available ... Hartford Consensus ," a concept paper published in the ... Trauma and Acute Care Surgery , official publication ...
(Date:6/19/2013)... -- Nearly 70 percent of Americans are ... than half take two, Mayo Clinic researchers say. ... prescribed, their study found. Twenty percent of patients ... to the findings, published online in the journal ... For audio and video of Dr. Jennifer St. ...
(Date:6/19/2013)... Effective Environmental Services and Clifford Woods, CEO, ... online links are devoted to a range of organic and ... Control Mold Magician and others. , Green products are easy ... the water as well as living plants. They contain beneficial ... accumulate at the bottom of a pond and render the ...
Breaking Medicine News(10 mins):Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2
... becomes a job search engine with the functionality of a job board. ... ... the current economic woes, employment sites are experiencing an increase in the ... for new job openings, Fresho has changed its business concept from a ...
... Howard G. Smith,announces that a class action lawsuit has ... District of New Jersey against PharmaNet Development,Group, Inc. ("PharmaNet" ... behalf of all,persons who purchased or otherwise acquired the ... 2008. The complaint alleges that the Company,and certain of ...
... the,health insurance industry now have a dedicated community ... education coursework, and ensure best,practice application of research ... "We were looking for an ... there was no dedicated group for the health ...
... women need more culturally targeted information, study finds , , ... almost six times more likely than white women to ... breast cancer treatment, a new report says. , Researchers ... that despite being just as involved with their doctor ...
... Nov. 21 Album Creative Studios, Inc., a full-service brand ... for small businesses. , , ... services, and tailored them to small businesses with a very ... Creative , founded in 2002, combines experience and proven brand-building ...
... Health Science Center at Houston will launch a new ... geriatrics training for physicians through a prestigious $2 million ... million in matching funds., "This will allow us to ... junior medical student to practicing physicians. With the reach ...
Cached Medicine News:Health News:Fresho.com Adapts As The Online Recruiting Market Heats Up 2Health News:Law Offices of Howard G. Smith Announces Class Action Lawsuit on Behalf of Investors of PharmaNet Development Group, Inc. 2Health News:Society of Insurance Research and Fletcher/CSI Create First Forum for Research Professionals in the Health Insurance Industry 2Health News:Society of Insurance Research and Fletcher/CSI Create First Forum for Research Professionals in the Health Insurance Industry 3Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
... the Flavavirus group pf viruses. This virus ... Dengue fever are the sudden onset of ... limbs, lymphadenopathy,maculopapular rash and retrobulbar pain.,This test ... aid in the diagnosis of anti-Dengue IgM ...
... The Dengue virus belongs to the Flavavirus ... commonly throughout the tropics.,Symptoms of Dengue fever ... pain in the back and limbs, lymphadenopathy,maculopapular ... for professional use as an aid in ...
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
For the rapid determination of human chorionic gonadotropin (hCG) in urine. The test strip is used to obtain a visual qualitative result....
Medicine Products: